New Clinical Trial for Mesothelioma Explained in Live Broadcast

On May 14, 2014, at 8 PM Eastern time, the Mesothelioma Applied Research Foundation will be holding a new installment of its “Meet the Mesothelioma Experts” series featuring Dr. Evan Alley of the University of Pennsylvania, who will discuss his new clinical trial available to pleural mesothelioma patients.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Mesothelioma Applied Research Foundation Logo
Research into PD-L1 inhibitors has already shown much promise in melanoma, renal cell carcinoma and lung cancer, evidencing both tumor shrinkage and durable response, and prompting a number of mesothelioma centers to open trials testing similar agents.

Alexandria, VA (PRWEB) May 06, 2014

On May 14, 2014, at 8 PM Eastern time, the Mesothelioma Applied Research Foundation will be holding a new installment of its “Meet the Mesothelioma Experts” series featuring Dr. Evan Alley of the University of Pennsylvania, who will discuss his new clinical trial available to pleural mesothelioma patients. The clinical trial will look into an agent that would inhibit the PD-L1 protein.

This installment of the “Meet the Mesothelioma Experts” is made possible by a generous educational grant by The Edgar Lomax Company.

PD-L1 is a protein believed to play a role in suppressing the immune system. Generally, it is associated with pregnancy and autoimmune diseases. In cancer, a high tumor expression of PD-L1 is linked with more aggressive disease and a poorer prognosis. Research into PD-L1 inhibitors has already shown much promise in melanoma, renal cell carcinoma and lung cancer, evidencing both tumor shrinkage and durable response, and prompting a number of mesothelioma centers to open trials testing similar agents.

Dr. Alley will discuss trial details in an interview with Mary Hesdorffer, Meso Foundation’s executive director and expert mesothelioma nurse practitioner. The interview can be listened to “live” by calling into a conference-call number. All listeners must RSVP ahead of time by visiting: http://www.curemeso.org/experts.

Dr. Alley is part of the Penn Mesothelioma and Pleural Program team and the interim chief of the Division of Hematology and Medical Oncology at Penn Presbyterian Medical Center.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. Medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)3 non-profit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund peer-reviewed mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer reviewed scientific research to establish effective treatments for mesothelioma and, ultimately, a cure for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.